)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Summit Therapeutics
Summit Therapeutics (SMMT) investor relations material
Summit Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary23 Feb, 2026
Executive summary
Advanced clinical development of ivonescimab, a bispecific antibody targeting PD-1 and VEGF, with multiple global Phase III trials in NSCLC, CRC, and other solid tumors underway or completed, and positive data supporting expansion into new indications.
BLA for ivonescimab in EGFR-mutant NSCLC accepted by FDA, with a PDUFA target date of November 14, 2026.
Commercial readiness activities ramping up in anticipation of potential US approval, with manufacturing process successfully transferred to a US-based facility.
Expanded collaborations with GSK, Revolution Medicines, and GORTEC, with new combination studies and patient dosing milestones achieved; ILLUMINE Phase III study in head and neck cancer to begin enrollment in early Q2 2026.
Over 4,000 patients dosed in clinical trials and more than 60,000 commercial patients in China.
Financial highlights
Year-end 2025 cash and short-term investments of $713.4 million, up from $412.3 million at year-end 2024, with no debt.
Q4 2025 GAAP operating expenses were $225 million, down from $234.2 million in Q3 2025; full-year 2025 GAAP operating expenses surged to $1,094.4 million, mainly due to $681.4 million in stock-based compensation.
Q4 2025 non-GAAP operating expenses were $113.3 million, up from $103.4 million in Q3 2025; full-year 2025 non-GAAP operating expenses increased to $362.0 million.
GAAP net loss was $1,079.6 million ($1.44/share) in 2025; non-GAAP net loss was $347.2 million ($0.46/share) in 2025.
Significant stock-based compensation adjustments in both R&D and G&A expenses.
Outlook and guidance
Interim PFS analysis for HARMONi-3 squamous cohort expected in Q2 2026; final PFS and interim OS data in H2 2026.
HARMONi-3 non-squamous cohort enrollment to complete in H2 2026, with final PFS data anticipated in H1 2027.
Continued expansion of the clinical pipeline, including new Phase III studies and novel combination regimens in 2026.
GSK and Revolution Medicines collaborations to initiate new combination trials in mid-2026.
Ivonescimab's bispecific design: expected benefits?
HARMONI-3 squamous interim PFS: market impact?
Funding strategy for planned Phase III expansion?
HARMONi-3 interim PFS disclosure plan?
FDA's current OS stance for HARMONi BLA?
Rationale for novel-novel combo strategy?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Summit Therapeutics earnings date
TD Cowen 46th Annual Health Care Conference2 Mar, 2026
Summit Therapeutics
Next Summit Therapeutics earnings date
TD Cowen 46th Annual Health Care Conference2 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Summit Therapeutics Inc., headquartered in Menlo Park, California, is a biopharmaceutical company engaged in the research and development of oncology therapies in the United States and the United Kingdom. Its lead pipeline product, ivonescimab, is a novel, bispecific antibody targeting both PD-1 and VEGF. Summit Therapeutics has also initiated two clinical trials with ivonescimab. Additionally, the company's product pipeline includes SMT-738, a novel class of precision antibiotics aimed at treating multidrug-resistant infections, including carbapenem-resistant Enterobacteriaceae infections. The company is headquartered in Menlo Park, California, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage